MVA Members

Immunitrack

Immunitrack is specialized  in next generation MHC-peptide  technologies for best-in-class in vitro peptide immunogenicity assessment for optimized biologics, vaccines and immunotherapies. New ways of measuring and preparing MHC-peptide complex are provided to ensure cost-effective development of best-in-class biologic therapeutics.

Immunitrack was established in 2013, and its expertise has been validated through more than a decade of academic research.  Companies that already benefit from Immunitrack’s platform technology include notable top 20 pharmaceutical and biotech companies